long intergenic non-protein coding RNA 1022Genealiases: []
Q-omics provides the consensus-scored LINC01022 profile across patient tissues and cancer cell-line models. LINC01022 expression is associated with patient survival in 5 of 34 cancer types, with the highest sampling consensus in LUSC. Among the 18 cancer types available for tumor–normal comparison, LINC01022 is differentially expressed in 7, with the highest sampling consensus in BRCA. Additionally, LINC01022 RNA expression shows 6,699 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight LUSC, BRCA, and ESCA as cancer lineages where LINC01022 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01022 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01022 survival associations across molecular data types. LINC01022 RNA expression shows survival associations in the most cancer types (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01022 RNA expression–survival associations across cancer types. High LINC01022 expression shows unfavorable associations in LUSC, ACC, KIRC and GBM, but favorable associations in PRAD. The LUSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .014). Together, the overview and detailed table identify LUSC as the clearest survival context for LINC01022 RNA expression.
This table summarizes LINC01022 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01022. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01022 shows lower tumor expression in COAD, ESCA and HNSC and higher tumor expression in BRCA, PRAD and LUAD. The BRCA box plot shows higher LINC01022 RNA expression in tumor versus normal tissue (log2 FC = +0.168, t-test p < 0.001).
This table shows molecular features associated with LINC01022 in patient tissues and cancer cell lines. In patient samples, LINC01022 shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set.
